Nowości w leczeniu farmakologicznym jaskry.
Autorzy: Katarzyna Samelska, Magdalena Kupis, Anna Zaleska-Żmijewska.

The Novelties in Glaucoma Pharmacotherapy.

Wydanie 3/2020
str. 25 – 28

Autorzy: Katarzyna Samelska, Magdalena Kupis, Anna Zaleska-Żmijewska

Katedra i Klinika Okulistyki Wydziału Lekarskiego Warszawskiego Uniwersytetu Medycznego.
Kierownik: prof. dr hab. n. med. Jacek P. Szaflik Samodzielny Publiczny Kliniczny Szpital Okulistyczny w Warszawie.
Kierownik: prof. dr hab. n. med. Jacek P. Szaflik..


Glaucoma is an optic nerve disease leading to persistent defects in visual field. Glaucoma may lead to blindness, if untreated. First step of the treatment is to pharmacologically decrease the intraocular pressure. The progress in medical therapy of glaucoma in the second half of 20th century has decreased the number of anti-glaucoma surgeries performed. The progress however is not ending at four main groups of drugs. The new solutions are being introduced, such as the new anti-glaucoma medications group: rho-kinase inhibitors, drugs donating nitric oxide and neuroprotective agents, such as used commonly citicoline. The innovative means of drugs administration, e.g. intracameral implants, help to improve the effect of the therapy.

Key words: glaucoma, latanoprostene bunod, netarsudil, neuroprotection, ripasudil.
Słowa kluczowe: jaskra, latanoprostenu bunod, netarsudil, neuroprotekcja, ripasudil.